Science Policy For All

Because science policy affects everyone.

Science Policy Around the Web – April 21, 2013

leave a comment »

By: Jennifer Plank

photo credit: limowreck666 via photopin cc

photo credit: limowreck666 via photopin cc

Our weekly linkpost, bringing you interesting and informative links on science policy issues buzzing about the internet.

FDA’s rejection of generic OxyContin may have side effects – With the patent on the original OxyContin ending, the FDA has declared that they will not approve generic versions of the drug. In order for drug developers to compete in the prescription pain relief market, they will have to develop abuse resistant forms of the drug. In 2010, Purdue Pharma LP, the developer of the original OxyContin, produced a form of the drug that includes a polymer that makes it impossible to snort and inject the drug. The patent on the drug resistant form expires in 2025.  (Nancy Shute and Audrey Carlsen)

Stereotype threat for girls and STEM – According to Facebook executive and author Sheryl Sandberg, women are being held back by what social scientists call a “stereotype threat”- an idea that suggests that the more we are aware of the stereotype, the more likely we are to act in accordance with it. Sandberg suggests that the stereotype threat is what is responsible for preventing women to pursue leadership roles and careers in highly technical field, such as computer science. A recent study looking at author gender and gender typing of projects suggests that publications from male authors were more highly regarded scientifically. The author also presents many links aiming to encourage interest in STEM. (Chris Gunter)

Gene patents are sabotaging the future of medicine – A case currently being debated by the Supreme Court, Association of Molecular Pathology v. Myriad Genetics, has the potential to influence how clinicians can report the results of genome wide sequencing to their patients. Currently, Myriad holds the patents on the BRCA1 and BRCA2 genes, which are associated with the onset of breast and ovarian cancers. Therefore, Myriad has a monopoly on all diagnostics and therapeutics related to the BRCA genes. The Association for Molecular Pathology states that a person has a right to know their own genetic code and should not have to have permission from patent holders to know the sequence of their own genes. The Supreme Court will rule on the case in late June. (Daniela Hernandez)

Have an interesting science policy link?  Share it in the comments!


Written by sciencepolicyforall

April 21, 2013 at 8:17 pm

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: